Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03472963 · ClinicalTrials.gov registry record · Phase 1
Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT03472963 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 35 participants.
The verdict
NCT03472963, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study is being conducted to determine if the uptake of anti-HIV medications called Genvoya® and darunavir is different at several body sites, including mucosal tissues.
Interventions
- DRUG Single dose of Genvoya® and a single 800 mg dose of Darunavir®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2018-04-27 |
| Est. Completion | 2019-03-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03472963
The ClinicalTrials.gov registry entry for NCT03472963 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Single dose of Genvoya® and a single 800 mg dose of Darunavir® is the first listed.
NCT03472963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03472963 about?
NCT03472963 is a clinical study titled "Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.". This study is being conducted to determine if the uptake of anti-HIV medications called Genvoya® and darunavir is different at several body sites, including mucosal tissues.
What is the current status of trial NCT03472963?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2018-04-27. Estimated completion is 2019-03-29.
What interventions are being tested in trial NCT03472963?
The interventions under investigation include: Single dose of Genvoya® and a single 800 mg dose of Darunavir® (DRUG).
Who is sponsoring clinical trial NCT03472963?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.